The effectively early detection and determination of disease progression of gastric cancer (GC) are still required. An emerging demand for identifying the novel targets adherent to cancer cells has been still challenged since those valuable profilings not only could act as for early gastric tumor discovery but also being potential therapeutic views. We have retrospectively analyzed GC biopsies to identify those specific target peptides in association with disease progression. We have detected the polypeptide by liquid mass technology initiated BIO-HIGH innovational assay technology for tumor-specific target peptide identification. We have validated the accessibility and feasibility of multiple target cytotoxic T-lymphocyte for the assessment of potential molecular markers by equally comparing the frequencies of tumor peptides' loci identified in 138 GC patients. The aim was to separate peripheral blood lymphocytes by density gradient centrifugation and use specific target peptides in in vitro culture of lymphocytes. The Cell Counting Kit-8 assay was set up to prove the lymphocytes' proliferation stimulated by identified peptides. Both of GC-specific peptide and shared peptide were detected in the peripheral blood, and the frequencies and quantities were correlated with disease status and cancer differentiation, in which BHGa1510 (78%), BHGa1310 (66%), BHGa0910 (57%), BHGa0310 (54%), BHGa0210 (40%), BHGa0810 (35%), BHGa0110 (33%), and BHGa1410 (30%) were apparently scoped out as high-frequency (HF) peptides could be potentially specific tumor markers. Moreover, BHGa1410 was significantly associated with cancer progression, and BHGa0910 and BHGa0210 were significantly associated with TNM stage. The IHC data have shown that both the HF BHGa1510 and HF BHGa1310 were expressions by 100% in contrast with paracancerous tissues of 40% (p < 0.05) and 33%, respectively (p < 0.05). Those specific peptide pools could be valued in assessment of advanced tumor and differential status in GC patients.

中文翻译：

---

新鉴定的高频肿瘤特异性肽相关特征在预测胃癌患者疾病状态中的临床意义

仍然需要有效地早期发现和确定胃癌（GC）的疾病进展。识别附着在癌细胞上的新靶标的新兴需求仍然受到挑战，因为这些有价值的分析不仅可以作为早期胃肿瘤发现，而且还可以作为潜在的治疗观点。我们回顾性分析了 GC 活检以确定与疾病进展相关的特定靶肽。我们通过液体质量技术检测多肽，开创了BIO-HIGH创新检测技术，用于肿瘤特异性靶肽鉴定。我们通过同等比较肿瘤肽的频率，验证了多靶细胞毒性 T 淋巴细胞用于评估潜在分子标志物的可及性和可行性。在 138 名 GC 患者中鉴定出基因座。目的是通过密度梯度离心分离外周血淋巴细胞，并在淋巴细胞的体外培养中使用特定的靶肽。建立细胞计数试剂盒-8 测定以证明淋巴细胞的增殖受到鉴定的肽的刺激。外周血中检测到GC特异性肽和共享肽，频率和数量与疾病状态和癌症分化相关，其中BHGa1510（78%）、BHGa1310（66%）、BHGa0910（57%）、 BHGa0310 (54%)、BHGa0210 (40%)、BHGa0810 (35%)、BHGa0110 (33%) 和 BHGa1410 (30%) 显然被排除在外，因为高频 (HF) 肽可能是潜在的特异性肿瘤标志物。此外，BHGa1410 与癌症进展显着相关，BHGa0910 和 BHGa0210 与 TNM 分期显着相关。IHC 数据显示，HF BHGa1510 和 HF BHGa1310 均表达 100%，而癌旁组织为 40%（p  < 0.05) 和 33%，分别为 ( p  < 0.05)。这些特定的肽库可用于评估 GC 患者的晚期肿瘤和差异状态。